| Molecular Formula: | |
|---|---|
| Molecular Formula | C15H17FN6O2S |
| Molecular Weight: | |
| Molecular Weight | 364.399 |
| COA: | |
| COA | Inquire |
| Targets: | |
| Targets | PI3K |
| Description: | |
| Description | CZC24832 is the first selective inhibitor of phosphoinositide 3-kinase γ (PI3Kγ) with efficacy in in vitro and in vivo models of inflammation. Extensive target- and cell-based profiling of CZC24832 revealed regulation of interleukin-17-producing T helper cell (T(H)17) differentiation by PI3Kγ, thus reinforcing selective inhibition of PI3Kγ as a potential treatment for inflammatory and autoimmune diseases. |
| Purity: | |
|---|---|
| Purity | 0.98 |
| Appearance: | |
| Appearance | Solid powder |
| Synonyms: | |
| Synonyms | CZC24832; CZC-24832; CZC 24832 |
| MSDS: | |
| MSDS | Inquire |
| InChIKey: | |
|---|---|
| InChIKey | RXRZPHQBTHQXSV-UHFFFAOYSA-N |
| InChI: | |
| InChI | InChI=1S/C15H17FN6O2S/c1-15(2,3)21-25(23,24)11-4-9(6-18-7-11)10-5-12(16)13-19-14(17)20-22(13)8-10/h4-8,21H,1-3H3,(H2,17,20) |
| Canonical SMILES: | |
| Canonical SMILES | CC(C)(C)NS(=O)(=O)C1=CN=CC(=C1)C2=CN3C(=NC(=N3)N)C(=C2)F |
| Current Developer: | |
| Current Developer | Cellzome Ltd. |
PI3Kα/mTOR-IN-1
(CAS: 1013098-90-2)
PI3Kα/mTOR-IN-1 is a potent dual inhibitor of PI3Kα/mTOR (Kis= 10.6 nM and 12.5 nM for mTOR and PI3Kα, respectively).
ETP-46321
(CAS: 1252594-99-2)
ETP-46321 is a potent and orally bioavailable PI3K α, δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after o...
TG100-115
(CAS: 677297-51-7)
TG100-115 is a potent and selective PI3K γ and -δ inhibitor (IC50 values of 83 and 235 nM, respectively) with no effect on PI3Kα or -β (IC50 values > 1 μM). As ...
CNX-1351
(CAS: 1276105-89-5)
CNX-1351 is a selective covalent Inhibitor of PI3Kα. In an end point assay, CNX-1351 potently inhibited PI3Kα and was 20−400 times less potent against β, γ, an...
LTURM 36
(CAS: 1879887-94-1)
LTURM 36 is a PI3-kinase δ inhibitor with IC50 value of 0.64μM. It shows anticancer activity in a renal cancer cell line.
Copanlisib
(CAS: 1032568-63-0)
Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. BAY 80-6946 inhibits the activation of the PI3K signaling pat...
AZD-8835
(CAS: 1620576-64-8)
AZD-8835 was selected as a clinical candidate for the treatment of PIK3CA-dependent cancers and is currently in phase I clinical trials. It is an orally bioavai...
GSK2636771
(CAS: 1372540-25-4)
GSK2636771 is an orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineopla...
Chemical Structure
